TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Vaginal Estradiol Use in Pessary Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Postmenopausal status~* Recent pessary fitting~* Office-based and home-based pessary care~Exclusion Criteria:~* Women \< 18 years old~* Women currently on hormone replacement therapy (pill, patch, pellet)~* Women currently using vaginal estradiol cream within the last 4 weeks~* Medical contraindications to vaginal estradiol including unevaluated vaginal bleeding~* Inability to apply vaginal estradiol cream~* Inability to provide informed consent~* Inability to comprehend written and/or spoken English or Spanish~* Inability to comply with study visit schedule

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control Group (Type: NO_INTERVENTION): Participants will receive standard pessary care. Participation requires follow up visit 6 months from initial baseline visit. At this visit, participants are asked about vaginal bleeding, degree of bother due to vaginal discharge, and degree of pessary discomfort and a physical exam is performed.
- Estrogen Group (Type: EXPERIMENTAL): Participants will receive standard pessary care, and those participants randomized to the experimental group will then be given a prescription for vaginal estradiol and instructed to apply it in the vagina nightly for two weeks and then twice weekly thereafter. Participation requires follow up visit 6 months from initial baseline visit. At this visit, participants are asked about vaginal bleeding, degree of bother due to vaginal discharge, and degree of pessary discomfort and a physical exam is performed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bowel Preparation Before Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* men~* women~* age 18-90 years~Exclusion Criteria:~* patients under 18 years~* acute colitis~* acute ileus~* seriously dementia~* patients from other counties

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Traditional bowel preparation with Laxabon
- B (Type: ACTIVE_COMPARATOR): Bowel preparation with nutritional drinks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Use of Teriparatide to Accelerate Fracture Healing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females must be menopausal (no menses within the last 12 months)~* Low energy fragility fractures of the pelvis, including anterior column, posterior column, inferior or superior rami, or sacrum~* Maximum of 2 weeks post fracture~* Mental status consistent with completing the study protocol~Exclusion Criteria:~* Currently receiving any treatment for osteoporosis, including estrogen and estrogenic-like compounds~* Received radiation treatment to any site at any time in the past~* Received chemotherapy for cancer at any time in the past~* Any active cancer~* Surgical repair (or attempted repair) of the fracture site in the pelvis~* Use of any bone-active medications~* Use of anticonvulsant therapy~* Use of immunosuppressants~* Any renal, gastrointestinal, liver, or metabolic bone disease~* Pregnancy~* High calcium, parathyroid hormone, or alkaline phosphatase, as based on laboratory results

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Injection (Type: ACTIVE_COMPARATOR): 30 participants will receive teriparatide (Forteo) injection pens.
- Placebo (Type: PLACEBO_COMPARATOR): 30 participants will receive placebo injection pens.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Surveillance Study of Patients With Newly Diagnosed Osteosarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~Each patient must meet all of the following inclusion criteria to be enrolled in the study:~* Male or female aged 2 to 40 years~* Confirmed pathological diagnosis of newly-diagnosed, nonmetastatic, resectable, primary, high-grade osteosarcoma~* Have completed definitive surgery (or other local ablation technique)~* Have a treatment regimen that includes mifamurtide and a minimum of 2 recognized chemotherapy agents in the treatment of osteosarcoma (cisplatin, doxorubicin, high-dose methotrexate or ifosfamide)~* Organ function deemed satisfactory to receive planned chemotherapy containing at minimum 2 of the recognized chemotherapy agents in the treatment of osteosarcoma~* Voluntary Written Consent~Exclusion Criteria~Patients meeting any of the following exclusion criteria are not to be enrolled in the study:~* Female patients who are lactating and breastfeeding or have a positive serum pregnancy test during the screening period~* History of pericarditis or pleuritis~* Have low-grade osteosarcoma or parosteal or periosteal sarcoma~* Have osteosarcoma associated with Paget's disease~* Current treatment with any anticancer investigational products at the time of enrollment in this study

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- High-grade osteosarcoma patients (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: A Study of ProQuad™ in Healthy Children in Korea (V221-023)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is in good health~* Subject has a negative clinical history for measles, mumps, rubella, varicella and zoster~Exclusion Criteria:~* Subject has previously received measles, mumps, rubella and/or varicella vaccine, either alone or in any combination~* Subject has any congenital or acquired immune deficiency, neoplastic disease or depressed immunity~* Subject has a history of seizure disorder~* Subject had exposure to measles, mumps, rubella, varicella and/or zoster in the last 4 weeks~* Subject has received an inactivated vaccine within the past 14 days~* Subject has received a live vaccine within the past 30 days~* Subject has received immune globulin within the past 5 months~* Subject has a recent history of fever (within the last 72 hours)

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 23 Months
- Healthy Volunteers: t

Study Arms:
- ProQuad™ (Type: EXPERIMENTAL): None
- M-M-R™ II and Varivax™ (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Respiratory Variations for Assessing Blood Withdrawal 2

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* adult patients of \> or equal 18 years~* dysmetabolic hyperferritinemia~* undergoing a therapeutic blood withdrawal~* health insured~* obese (body mass index \> or equal 30Kg/m²)~Exclusion Criteria:~* pregnancy~* transthoracic echogenicity unsuitable for measuring the inferior vena cava diameters~* clinical signs of active exhalation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- obese patients with dysmetabolic hyperferritinemia (Type: None): PATIENTS: obese patients with dysmetabolic hyperferritinemia undergoing a therapeutic bleeding.~INTERVENTIONS: The investigators performed ultrasound measurements (echography) and collected clinical parameters before and after a 300 to 500ml therapeutic bleeding, during a standardized respiratory maneuver.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prediction of Cytomegalovirus (CMV) Reactivation in Intensive Care Unit (ICU) by Immunological Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* ICU admission for more than 3 days~* Admission for septic shock~* Patient with mechanical invasive ventilation~Exclusion Criteria:~* Immunodepression status before ICU admission (chemotherapy, bone marrow or solid organ transplantation, long time corticosteroid treatment, immunosuppressant therapy, HIV infection)~* Seronegative patient for CMV~* Patient under anti-virus treatment~* Patient under guardianship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Septic shock patients (Type: None): Septic shock patients staying over 3 days mechanically ventilated in the ICU

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adequate complete blood counts, liver and renal function.~* 12-lead electrocardiogram (ECG) within normal limits~* Female subjects must be of non-childbearing potential; e.g. post-menopausal or pre-menopausal with surgical sterilization~* Male subjects agree to use appropriate contraception~* Willing to provide written informed consent and willing to comply with study requirements~* Nonsmokers for at least 5 years before screening~Exclusion Criteria:~* Any uncontrolled or serious disease, or any medical or surgical condition, that may interfere with participation in the clinical study and/or put the subject at significant risk~* Received an investigational agent within 90 days before the first dose of study drug or are in follow-up of another clinical study~* Active serious mental illness or psychiatric disorder requiring current pharmacological intervention~* History or evidence of alcohol or drug abuse within 12 months before screening.~* History of intolerance to SC injection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- ALN-AAT (Type: ACTIVE_COMPARATOR): None
- Sterile Normal Saline (0.9% NaCl) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Recurrence Of Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of both genders.~* Age 18 years and 70 years.~* Postoperative Karnofsky Performance Status \>=70.~* Diagnosis of recurrent GBM (World Health Organization \[WHO\] grade IV astrocytoma).~* Diagnosis confirmed by the reference histopathology.~* Total or subtotal resection of tumor mass, confirmed by assessment of the neurosurgeon and by postoperative radiological assessment.~* Amount of non-necrotic tissue for lysate preparation and DC loading \>= 1 gr, stored at -80°C.~* Corticosteroids daily dose \<= 4 mg during the 2 days prior to leukapheresis.~* Life expectancy \> 3 months.~* Signed informed consent.~Exclusion Criteria:~* Pregnancy.~* Participation in other clinical trials with experimental drugs simultaneously or within 1 month before this trial entry.~* Presence of acute infection requiring active treatment.~* Mandatory treatment with corticosteroids or salicylates in anti-inflammatory dose.~* Presence of sub-ependymal diffusion of the tumor.~* Haematology: leukocytes \< 3,000/μl, lymphocytes \< 500/μl, neutrophils \< 1,000/μl, hemoglobin \<9 g/100 ml, thrombocytes \< 100,000/μl 2 days prior to leukapheresis.~* Documented immune deficiency.~* Documented autoimmune disease.~* Positive serology for HIV or hepatitis B or C.~* Allergies to any component of the DC vaccine.~* Known intolerance to TMZ.~* Other active malignancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Immunotherapy (Type: EXPERIMENTAL): Autologous DC loaded with a autologous tumor lysate, in order to stimulate the immune response of the patient.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: TEAMS-BP (The Enhancement of Social Networks to Augment Management of Stroke-Blood Pressure)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. First acute ischemic stroke defined clinically with support from imaging if necessary~2. 21 years of age or older~3. Within 14 days after stroke~4. History of hypertension or has been newly prescribed blood pressure medications during index admission~Exclusion Criteria:~1. Prior ischemic or hemorrhagic stroke~2. NIHSS \> 21~3. Significant aphasia (Score\>1 on the language section of the NIHSS)~4. Medical conditions for which death is likely within 6 months~5. Does not have capacity to consent for the project or participate in survey interview~6. Diagnosis of dementia~7. Patient has no phone or incapable of using text messages~8. Patient has opted out of participating in research noted within MGB Epic EHR system

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Social Network Counseling (Type: EXPERIMENTAL): The index patient and influential social network members will meet via Zoom 3 times over the course of 3 months with a clinical research nurse for teamwork counseling and blood pressure education.
- Individual Counseling (Type: ACTIVE_COMPARATOR): The index patient will meet via Zoom 3 times over the course of 3 months with a clinical research nurse for blood pressure education.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes inadequately controlled or intolerant to metformin~* Obtaining informed consent~* Aged between 18 and 70 years~* BMI between 20 and 45 kg / m²~Exclusion Criteria:~* Contraindication to nuclear magnetic resonance (NMR):~* Carrying a metallic foreign body (pacemaker, valve, intraocular equipment, clips)~* Allergy to Gadolinium / Secretin~* Pregnancy or breastfeeding~* Contraindication to treatment with incretinomimetic:~* Hypersensitivity to the active substance or to any of the excipients~* Severe Gastroparesis~* Severe renal impairment~* History of Surgery (gastroduodenal, pancreatic or ileocecal)~* Presence or history of pancreatic disease~* Active alcoholism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sulfonylurea (Type: ACTIVE_COMPARATOR): Patient will received metformine with sulfonylurea
- Incretinomimectics (Type: ACTIVE_COMPARATOR): Patients will received metformin with sulfonylurea with GLP-1 analogue
- DPP-4 inhibitors (Type: ACTIVE_COMPARATOR): Patients will received metformin with DPP-4 inhibitors

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Retrospective Evaluation of Carvedilol Versus Captopril in CHF Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: DEFINED_POPULATION
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria: Children aged 0-18 years with a cardiac defect resulting in a left-to-right shunt (i.e. ventricular septal defect) who develop congestive heart failure. Patient must have been treated with one of the study medications: carvedilol, digoxin, or furosemide.~-~Exclusion Criteria: Patients who are not between 0-18, who do not have a defect resulting in left-to-right shunt, who do not have congestive heart failure and who have not been treated with one of the study medications: carvedilol, digoxin, or furosemide.~-

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: BELIEVE Study: Nesiritide and Post Myocardial Infarction Left Ventricular Modeling

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with acute ST elevation myocardial infarction of at least \> 2mV ST elevation in two or more anterior precordial leads, with successful revascularization (Thrombolysis in Myocardial Infarction \[TIMI\] grade 3 flow) of the lesion within 24 hours of chest pain as documented by coronary angiogram.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of TEPSO® Socks in Improving Palmoplantar Pustulosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Palmoplantar pustulosis present for at least one year~* Symmetrical foot lesions with at least 5% of the skin surface involvement~* Difference less than or equal to 10% extension of lesions on both sides of the body~* Suspension for over 3 months from start of the study of any systemic drugs for psoriasis, immunosuppressive treatments (cyclosporine, systemic steroids), psoralen plus ultraviolet A irradiation (PUVA) or ultraviolet B phototherapy (UVB)~Exclusion Criteria:~* Nonsymmetrical foot lesions or less than 5% of the skin surface involvement~* Difference of more than 10% extension of lesions on both sides of the body~* Patients who have performed, within 3 months before inclusion in the study, treatments with systemic drugs for psoriasis, immunosuppressive treatments (cyclosporine, systemic steroids), psoralen plus ultraviolet A irradiation (PUVA) or ultraviolet B phototherapy (UVB)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- TEPSO socks (Type: EXPERIMENTAL): This arm include all patients sides (left or right) treated with TEPSO socks.
- Standard socks (Type: PLACEBO_COMPARATOR): This arm include all patients sides (left or right) treated with standard cotton socks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues